These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19671737)

  • 1. Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor.
    Carden CP; Molife LR; de Bono JS
    Mol Cancer Ther; 2009 Aug; 8(8):2077-8. PubMed ID: 19671737
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin-like growth factor receptor inhibitors: baby or the bathwater?
    Yee D
    J Natl Cancer Inst; 2012 Jul; 104(13):975-81. PubMed ID: 22761272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.
    Hofmann F; García-Echeverría C
    Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The decline and fall of the IGF-I receptor.
    Baserga R
    J Cell Physiol; 2013 Apr; 228(4):675-9. PubMed ID: 22926508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The insulin-like growth factor-I receptor as a target for cancer therapy.
    Baserga R
    Expert Opin Ther Targets; 2005 Aug; 9(4):753-68. PubMed ID: 16083341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Customizing the targeting of IGF-1 receptor.
    Baserga R
    Future Oncol; 2009 Feb; 5(1):43-50. PubMed ID: 19243297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the type I insulin-like growth factor system for breast cancer therapy.
    Sachdev D
    Curr Drug Targets; 2010 Sep; 11(9):1121-32. PubMed ID: 20545608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy of the insulin-like growth factor-1 receptor in cancer.
    Paz K; Hadari YR
    Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.
    Zha J; O'Brien C; Savage H; Huw LY; Zhong F; Berry L; Lewis Phillips GD; Luis E; Cavet G; Hu X; Amler LC; Lackner MR
    Mol Cancer Ther; 2009 Aug; 8(8):2110-21. PubMed ID: 19671761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
    Heidegger I; Massoner P; Sampson N; Klocker H
    Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between IGF-1R and other tumor promoting pathways.
    Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y
    Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of focal adhesion kinase inhibitors in cancer therapy.
    Ma WW
    Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.
    Wang Y; Hailey J; Williams D; Wang Y; Lipari P; Malkowski M; Wang X; Xie L; Li G; Saha D; Ling WL; Cannon-Carlson S; Greenberg R; Ramos RA; Shields R; Presta L; Brams P; Bishop WR; Pachter JA
    Mol Cancer Ther; 2005 Aug; 4(8):1214-21. PubMed ID: 16093437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
    Iams WT; Lovly CM
    Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.
    Sachdev D; Yee D
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):27-39. PubMed ID: 16947084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.